Subscribe to the 100% free rdnewsNOW daily newsletter!
Prime Minister Justin Trudeau. (The Canadian Press)
companies and universities getting funding

Federal government spending $192-million to produce COVID-19 vaccines

Mar 23, 2020 | 11:06 AM

OTTAWA, ON – Prime Minister Justin Trudeau says the federal government is planning to invest $192 million to help create and produce vaccines for COVID-19.

The money will be distributed to a number of different companies and universities in the drive to find a way to stop the illness’s spread.

“Canada is home to some of the most skilled and brightest researchers in the world, who are working hard to develop countermeasures that will protect the health and safety of Canadians and support international efforts to fight this pandemic. We are all in this together, and need to be doing our part to prevent the spread of the virus,” Trudeau said.

$192 million in new projects that will be prioritized under the new Strategic Innovation Fund COVID-19 stream to deliver direct support to Canadian companies for large-scale projects. These companies include:

· AbCellera, a Vancouver-based biotech company that has built the world’s leading technology for antibody discovery, is at the forefront of developing antibody-based drugs to treat and prevent COVID-19. AbCellera’s technology is being used to search blood samples of patients who have recovered from COVID-19 to find naturally-produced antibodies that can be used for treatment and prevention.

· Medicago, a Quebec City-based company with 20 years of experience in plant-based vaccines and therapeutics, that has identified a viable plant-based vaccine candidate currently at the pre-clinical testing phase. Funding will allow Medicago to rapidly move forward on clinical trials and then quickly shift to scaling up production for pandemic response.

· Funding for the University of Saskatchewan’s Vaccine and Infectious Disease Organization – International Vaccine Centre (VIDO-InterVac), one of the largest and most advanced infectious disease research facilities in the world. With $11 million in funding from the Canada Foundation for Innovation, VIDO-InterVac will be able to strengthen its existing expertise in coronavirus research and to help develop a vaccine for COVID-19. An additional $12 million from Western Economic Diversification’s Regional Economic Growth Through Innovation program will help VIDO-InterVac expand its bio-manufacturing capacity to support clinical trials.

· Funding of $15 million for the National Research Council of Canada to upgrade its Human Health Therapeutics facility in Montréal to develop, test and scale-up promising vaccine candidates to be ready for industrial production. This will involve certifying the facility for Good Manufacturing Practice (GMP) quality assurance to ensure that their human pharmaceuticals and biologics, including vaccines, are consistently produced and controlled. This certification will support a more effective roll-out and production of vaccines, and help ensure that any vaccines produced by the facility can be made available to Canadians and people around the world more quickly.

· Support for BlueDot, a Toronto-based digital health firm, with a first-of-its-kind global early warning technology for infectious diseases. The company was one of the first in the world to identify the spread of COVID-19. The Government of Canada, through the Public Health Agency of Canada, will use its disease analytics platform to support modelling and monitoring of the spread of COVID 19, and to inform government decision-making as the situation evolves.

The federal government is also unveiling advertisements to hammer home the importance of social distancing.

The move is in response to concerns some people are continuing to ignore calls for distancing to prevent the spread of COVID-19.

Trudeau says the government will take whatever steps are needed to get people to comply, including enforcement.

(With file from The Canadian Press and government media release)